FOLR1: Emerging Targets and CAR-T Technology Potential in Targeted Therapy of Ovarian Cancer

FOLR1: Emerging Targets and CAR-T Technology Potential in Targeted Therapy of Ovarian Cancer

Epithelial ovarian cancer (OvCa) is one of the most deadly malignant tumors in the female reproductive system. It is difficult to diagnose early, has a high recurrence rate, and has a low five-year survival rate, making it a difficult problem to be overcome in the field of oncology. In recent years, with the rapid development of molecular biology and immunotherapy, folate receptor 1 (FOLR1, also known as FRα) has gradually become a hot spot in the study of targeted therapy of ovarian cancer due to its specific expression in epithelial tumors.

Biological characteristics and expression pattern of FOLR1

FOLR1 is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that participates in cell proliferation and metabolism by transporting folic acid. It is abnormally highly expressed in epithelial tumors such as ovarian cancer, while its expression level is extremely low in normal tissues. This characteristic makes it an ideal tumor-specific target. Studies have shown that in high-grade serous ovarian cancer (HGSOC), the expression rate of FOLR1 is close to 100%, and the expression intensity is positively correlated with the malignancy of the tumor. This differential expression pattern not only provides a potential marker for the early diagnosis of ovarian cancer, but also lays a molecular foundation for the development of targeted treatment strategies.

Validation of FOLR1 as a CAR-T target

Chimeric antigen receptor T cell (CAR-T) technology modifies T cells through genetic engineering, enabling them to specifically recognize and kill tumor cells. In the study of FOLR1-targeted CAR-T therapy, researchers screened candidate molecules with high affinity and specificity for FOLR1 by constructing a variety of CAR structures. These CAR-T cells showed strong killing activity against FOLR1-positive ovarian cancer cells in in vitro experiments, and had no significant toxicity to FOLR1-negative cells, which preliminarily verified their safety and effectiveness. In addition, animal model experiments further confirmed that FOLR1-targeted CAR-T cells can effectively inhibit tumor growth and prolong survival, indicating its great potential in the treatment of ovarian cancer.

CAR-T technology optimization and challenges

Although FOLR1-targeted CAR-T therapy has shown significant efficacy, its clinical application still faces multiple challenges. First, the optimization of CAR structure needs to balance affinity and safety to avoid off-target toxicity caused by nonspecific activation. Secondly, immunosuppressive factors in the tumor microenvironment (such as Treg cells and PD-L1 expression) may weaken the persistence and function of CAR-T cells. Therefore, combining immune checkpoint inhibitors or modifying CAR-T cells to enhance their anti-exhaustion ability has become an important direction of current research. In addition, how to improve the infiltration and penetration ability of CAR-T cells in solid tumors is also the key to breaking through the bottleneck of ovarian cancer treatment.

Future Outlook

FOLR1, as a specific target for ovarian cancer treatment, combined with the precision and efficiency of CAR-T technology, provides new possibilities for breaking through existing treatment limitations. With the development of gene editing technology (such as CRISPR/Cas9) and synthetic biology, CAR-T cells can be engineered in the future to achieve multi-target collaborative recognition, dynamic regulation function and long-term memory formation, further enhancing their anti-tumor activity. In addition, nanocarrier delivery systems or bispecific antibody design based on FOLR1 may also open up new avenues for ovarian cancer treatment.

FOLR1-targeted CAR-T technology has brought a revolutionary breakthrough in the treatment of ovarian cancer. The combination of its specific expression pattern and CAR-T technology not only provides a new strategy for solving the problems of ovarian cancer recurrence and drug resistance, but also injects new vitality into the development of tumor immunotherapy. With the deepening of research and the improvement of technology, FOLR1 is expected to become a core target for precision treatment of ovarian cancer.